Akebia Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
AKBA$0.54+1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| Three Months Ended March 31, | ||
|---|---|---|
| (dollars in thousands, except per share amounts) | 2024 | 2023 |
| Revenues | ||
| Product revenue, net | $31,009 | $34,706 |
| License, collaboration and other revenue | 1,598 | 5,299 |
| Total revenues | 32,607 | 40,005 |
| Cost of goods sold | ||
| Cost of product and other revenue | 2,594 | 11,178 |
| Amortization of intangible asset | 9,011 | 9,011 |
| Total cost of goods sold | 11,605 | 20,189 |
| Operating expenses: | ||
| Research and development | 9,731 | 19,686 |
| Selling, general and administrative | 25,438 | 25,053 |
| License | 711 | 568 |
| Restructuring | 58 | 106 |
| Total operating expenses | 35,938 | 45,413 |
| Loss from operations | (14,936) | (25,597) |
| Other income (expense) | ||
| Interest expense | (2,498) | (1,561) |
| Other income | 95 | 282 |
| Change in fair value of warrant liability | (129) | — |
| Loss on extinguishment of debt | (517) | — |
| Net loss before income taxes | $(17,985) | $(26,876) |
| Net loss | $(17,985) | $(26,876) |
| Comprehensive loss | $(17,985) | $(26,876) |
| Net loss per share: | ||
| Basic and diluted | $(0.09) | $(0.15) |
| Weighted average common shares outstanding: | ||
| Basic and diluted | 204,955,151 | 184,768,983 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.